GlassScriptPhysician profile
Brian Jochim
NPI 1306109327
$2,081.07
in general payments reported to CMS, 2019-2025
27 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $737 · 2022: $769 · 2023: $121 · 2024: $105 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $627.06 | 2022-2023 | Zimhi, Lucemyra |
| Abbvie INC. | $218.07 | 2021-2022 | |
| Corium, LLC | $148.09 | 2025 | Azstarys |
| Novo Nordisk INC | $107.88 | 2021-2022 | |
| Braeburn INC. | $105.45 | 2024 | Brixadi |
| Lilly USA, LLC | $104.56 | 2021-2022 | |
| Alkermes, INC. | $94.87 | 2021-2022 | |
| Esperion Therapeutics, INC. | $69.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.75 | 2021-2022 | |
| Pfizer INC. | $62.57 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $57.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $56.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.01 | 2021 | |
| Collegium Pharmaceutical, INC. | $38.50 | 2025 | Jornay Pm |
| Tris Pharma INC | $34.46 | 2025 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.38 | 2022-2025 | Enflonsia, Vaxelis, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $28.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.40 | 2021 | |
| Amarin Pharma, INC. | $22.83 | 2021 | |
| Hologic Sales and Service, LLC | $21.63 | 2025 | Aptima |
| Supernus Pharmaceuticals, INC. | $19.70 | 2021 | |
| Astellas Pharma US INC | $17.48 | 2021 | |
| Amgen INC. | $16.97 | 2022 | |
| Acadia Pharmaceuticals INC | $16.77 | 2025 | Daybue |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jochim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.